New ‘Heavily Mutated’ B.1.1.529 Covid-19 Coronavirus Variant Spreading In South Africa
The World Health Organization (WHO) will meet tomorrow to determine if the B.1.1.529 SARS-CoV-2 variant should be considered a variant of interest or concern.
ConclusionVariations of pH occurred in the majority (79.7%) of patients admitted with COVID-19. The patients experienced all the type of acid –base disorders, notably metabolic and respiratory alkalosis were the most common alterations in this group of patients.
Biochem Biophys Res Commun. 2022 Jan 15;593:52-56. doi: 10.1016/j.bbrc.2022.01.038. Online ahead of print.ABSTRACTCOVID-19, the respiratory infection caused by the novel coronavirus SARS-CoV-2, presents a clinical picture consistent with the dysregulation of many of the pathways mediated by the metalloprotease ADAM17. ADAM17 is a sheddase that plays a key role in the modulation of ACE2, the receptor which also functions as the point of attachment leading to cell entry by the virus. This work investigates the possibility that ADAM17 dysregulation and attachment of the SARS-CoV-2 virion to the ACE2 receptor are linked events...
This study is the first to provide a basis for the higher infectivity of the new SARS-CoV-2 variants and provides a strong impetus for the development of novel drugs against them.PMID:35063482 | DOI:10.1016/j.ijbiomac.2022.01.059
Conclusions. SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
This report describes COVID-19 vaccine effectiveness time frames among people who received their first and second doses of the vaccine series, and effectiveness of third vaccine doses during both Delta- and Omicron-predominant periods.
Condition: COVID-19 Intervention: Diagnostic Test: real time PCR Sponsor: Sohag University Recruiting
This report describes COVID-19 incidence rate ratios for unvaccinated versus fully vaccinated persons with and without booster vaccine doses during the emergence of the Omicron variant.
We present the examples of structure-based design of Pfizer's novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck's nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies.PMID:35058587 | DOI:10.1038/s41401-021-00851-w
In this study, we collected 3,508 nasopharyngeal swab samples from 3,249 patients who visited the Yamanashi Central Hospital in Japan from March 1, 2020 to February 28, 2021. We performed multiplex polymerase chain reaction (PCR) using the FilmArray Respiratory Panel and singleplex quantitative reverse transcription PCR targeting SARS-CoV-2 to detect respiratory disease-associated pathogens. At least one pathogen was detected in 246 (7.0%) of the 3,508 samples. Eleven types of pathogens were detected in the samples collected from March-May 2020, during which non-pharmaceutical interventions were not well implemented. In co...
Int J Mol Med. 2022 Mar;49(3):33. doi: 10.3892/ijmm.2022.5088. Epub 2022 Jan 21.ABSTRACTThe pandemic caused by the severe acute respiratory syndrome coronavirus (SARS‑CoV‑2), responsible for coronavirus disease 2019 (COVID‑19) has posed a major challenge for global health. In order to successfully combat SARS‑CoV‑2, the development of effective COVID‑19 vaccines is crucial. In this context, recent studies have highlighted a high COVID‑19 mortality rate in patients affected by β‑thalassemia, probably due to their co‑existent immune deficiencies. In addition to a role in the severity of SARS‑CoV‑2 ...